Clinical Trial Update: Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for depsipeptide in unresectable recurrent or metastatic squamous cell carcinoma of the head and neck; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip and Oral Cavity
• Squamous Cell Carcinoma of the Oropharynx

Drugs mentioned

• depsipeptide (depsipeptide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx | Phase 2 | Status: COMPLETED | Results posted: 2015-05-19